Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Weleader Biomedical CoROCO:7713 +2.67%66 EV-to-FCF is 22.95 as of Aug. 23, 2026, which is 28% below its 10-year median of 31.68. GuruFocus rates ROCO:7713 with a GF Score™ of 66/100 and a GF Value™ of NT$74.55 (Fairly Valued). The stock has 5 warning signs investors should review. Among 404 Medical Devices & Instruments companies, Weleader Biomedical Co ranks better than 53.47% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Weleader Biomedical Co's Enterprise Value is NT$4,102 Mil.
Weleader Biomedical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was NT$179 Mil. Therefore, Weleader Biomedical Co's EV-to-FCF for today is 22.95.
The historical rank and industry rank for Weleader Biomedical Co's EV-to-FCF or its related term are showing as below:
ROCO:7713'
s EV-to-FCF Range Over the Past 10 Years
Min: -2541.92 Med: 31.68 Max: 182.61
Current: 22.95
During the past 6 years, the highest EV-to-FCF of Weleader Biomedical Co was 182.61. The lowest was -2541.92. And the median was 31.68.
ROCO:7713's EV-to-FCF is ranked better than 53.47% of 404
companies
in the Medical Devices & Instruments industry
Industry Median: 24.62
vs ROCO:7713: 22.95
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Weleader Biomedical Co (ROCO:7713) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Weleader Biomedical Co's PE Ratio (TTM) for today is calculated as:
Weleader Biomedical Co's share price for today is NT$73.00.
Weleader Biomedical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$5.165.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Weleader Biomedical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Weleader Biomedical Co EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Weleader Biomedical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Weleader Biomedical Co's EV-to-FCF falls into.
Weleader Biomedical Co's current Enterprise Value is NT$4,102 Mil.
Weleader Biomedical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$179 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Weleader Biomedical Co (ROCO:7713) has a EV-to-FCF of 22.95 as of Aug. 23, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Weleader Biomedical Co and its competitors. This is 28% below median its historical median of 31.68. According to the industry distribution chart, Weleader Biomedical Co ranks #188 out of 404 companies in the Medical Devices & Instruments industry, placing it in the top 46.5%.
Is Weleader Biomedical Co's EV-to-FCF too high?
Weleader Biomedical Co's current EV-to-FCF of 22.95 is 28% below median its 10-year median of 31.68. The Medical Devices & Instruments industry median EV-to-FCF is 24.62. Weleader Biomedical Co's value of 22.95 is 6.8% below this industry median. Based on the distribution chart, Weleader Biomedical Co ranks #188 out of 404 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Weleader Biomedical Co has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Weleader Biomedical Co's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Weleader Biomedical Co ranks #188 out of 404 companies for EV-to-FCF. This puts Weleader Biomedical Co in the upper half of its industry. The industry median EV-to-FCF is 24.62. Weleader Biomedical Co's value of 22.95 is 6.8% below this benchmark. While the company's 10-year median is 31.68 vs. the industry median of 24.62, Weleader Biomedical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 24.62, based on 404 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Weleader Biomedical Co's current EV-to-FCF of 22.95 is 6.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Weleader Biomedical Co and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 24.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Weleader Biomedical Co's current EV-to-FCF is 22.95, which is 28% below median its own 10-year median of 31.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Weleader Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Weleader Biomedical Co (ROCO:7713) is currently considered Fairly Valued. The stock's GF Value™ is NT$74.55, compared to a current price of NT$73.00 — trading 2.1% below its estimated fair value. The current EV-to-FCF is 22.95, which is 28% below median its 10-year median of 31.68 and 6.8% below the Medical Devices & Instruments industry median of 24.62. Weleader Biomedical Co's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Weleader Biomedical Co (ROCO:7713), the current EV-to-FCF is 22.95 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Weleader Biomedical Co (ROCO:7713) Overvalued in 2026?
Based on GuruFocus' analysis, Weleader Biomedical Co stock appears to be undervalued.
The current stock price of NT$73.00 is trading 2.1% below its estimated GF Value™ of NT$74.55.
GuruFocus considers Weleader Biomedical Co to be Fairly Valued.
Key valuation signals for ROCO:7713:
EV-to-FCF: 22.95 (28% below median its 10-year median of 31.68)
GF Value™: NT$74.55 vs. price of NT$73.00 (2.1% below fair value)
Industry Position: 6.8% below the Medical Devices & Instruments median (#188 of 404)
No single metric tells the full story. See the ROCO:7713 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Weleader Biomedical Co Ltd is mainly engages in the sales of medical testing reagents and medical devices; and the leasing of testing instruments. The reportable segments of the Group are: The Company, which includes sale of testing reagents, and provision of testing instruments and services; and Health Leader, which includes sale of dietary supplements and testing reagents, and provision of information and professional services. It derives majority revenue from the Company segment. Geographically, the company operates and generates revenue from Taiwan.
66GF Score
Get the complete analysis for ROCO:7713
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7713 has been successfully added to your 
